Real-world Drug Regimens for Multiple Myeloma in a Swiss Population (2012 to 2017): cost-outcome description
View ORCID ProfileKlaus Eichler, View ORCID ProfileRoland Rapold, View ORCID ProfileSimon Wieser, View ORCID ProfileOliver Reich, View ORCID ProfileEva Blozik
doi: https://doi.org/10.1101/19008383
Klaus Eichler
1Winterthur Institute of Health Economics, Zurich University of Applied Sciences, Gertrudstrasse 15, CH-8401 Winterthur, Switzerland
Roland Rapold
2Helsana Insurances, Health Sciences, Switzerland
Simon Wieser
1Winterthur Institute of Health Economics, Zurich University of Applied Sciences, Gertrudstrasse 15, CH-8401 Winterthur, Switzerland
Oliver Reich
2Helsana Insurances, Health Sciences, Switzerland
Eva Blozik
2Helsana Insurances, Health Sciences, Switzerland
Article usage
Posted October 08, 2019.
Real-world Drug Regimens for Multiple Myeloma in a Swiss Population (2012 to 2017): cost-outcome description
Klaus Eichler, Roland Rapold, Simon Wieser, Oliver Reich, Eva Blozik
medRxiv 19008383; doi: https://doi.org/10.1101/19008383
Subject Area
Subject Areas
- Addiction Medicine (317)
- Allergy and Immunology (621)
- Anesthesia (162)
- Cardiovascular Medicine (2302)
- Dermatology (205)
- Emergency Medicine (372)
- Epidemiology (11640)
- Forensic Medicine (10)
- Gastroenterology (686)
- Genetic and Genomic Medicine (3640)
- Geriatric Medicine (342)
- Health Economics (625)
- Health Informatics (2337)
- Health Policy (921)
- Hematology (337)
- HIV/AIDS (761)
- Medical Education (361)
- Medical Ethics (101)
- Nephrology (394)
- Neurology (3395)
- Nursing (193)
- Nutrition (512)
- Oncology (1784)
- Ophthalmology (528)
- Orthopedics (212)
- Otolaryngology (284)
- Pain Medicine (226)
- Palliative Medicine (66)
- Pathology (441)
- Pediatrics (1014)
- Primary Care Research (411)
- Public and Global Health (6037)
- Radiology and Imaging (1238)
- Respiratory Medicine (815)
- Rheumatology (370)
- Sports Medicine (319)
- Surgery (390)
- Toxicology (50)
- Transplantation (171)
- Urology (144)